U6 snRNP inhibits the premature cleavage and polyadenylation of pre-mRNAs (ChIP-Seq)
RNAPII ChIP-seq analysis in U2 and U6 antisense morpholino oligonucleotide (AMO)-treated HeLa cells in comparison to negative control (NC) AMO To investigate if U2 or U6 AMO treatment caused transcription defect, we carried out RNAPII ChIP-seq analysis in control, U2 and U6 AMO treated HeLa cells Overall design: ChIP-seq analysis was conducted in HeLa cells using an antibody specific to the RNAPII CTD (C-terminal domain). Two biological replicates were performed for each sample.